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Section I: Introduction 
1) Definition of the Program 
“Diabetes Guidelines Implementation Toolkit” is a capstone project aimed to help the Grady 
North Fulton Health Center implement the American Diabetes Association (ADA) “Standards in 
Medical Care in Diabetes, 2011” guidelines. In addition, this toolkit can be used to implement 
the ADA diabetes guidelines in any other primary or community healthcare facility to improve 
diabetes care. 
Grady North Fulton Health Center is one of eight Neighborhood Health Centers of Grady Health 
System in Georgia. The center is located in North Fulton County on Roswell Road, Sandy 
Springs. Primary care services provided by the center include family medicine, pediatrics, and 
women's health (OB/GYN). It also provides laboratory services, translation services, and 
financial counseling. In 2010, there were 8,682 patient visits to Grady North Fulton Health 
Center, and that accounts for 6.3% of the clinic visit in all neighborhood clinics. 
Grady Health System is aiming to implement the Patient Centered Medical Home (PCMH) 
model in its Neighborhood Health Centers, and Grady North Fulton Health Center is now going 
through the process of being certified by the National Committee of Quality Assurance (NCQA) 
as a Patient Centered Medical Home. 
To become PCMH certified the health center is required to implement evidence-based 
guidelines for three of the most common diseases treated at the facility.  This implementation 
toolkit will help to fulfill this standard and achieve the PCMH certification. 
A toolkit is defined as a collection of information, resources, and recommendations for a 
specific subject area or activity; or as a set of tools designed to be used together or for a 
particular purpose. A toolkit is used, intended or design to train, implement, assess, evaluate 
and survey the individuals using it. 
Once the decision is made to put the evidence-based diabetes guidelines into practice, this 
implementation toolkit will serve as a guide to help to direct the process of implementation. 
The toolkit will suggest practical ways to implement the use of the guidelines, and it will provide 
resources and template materials such as information handouts, flow sheets, referral forms, 
sample patient letters, etc. 
 The American Diabetes Association (ADA) annually publishes the “Standards in Medical Care in 
Diabetes” in its magazine Diabetes Care. This document is intended to guide physicians in the 
evidence-based best practices to care for diabetic patients. The clinical team at Grady North 
Fulton Health Center selected these guidelines because they are well accepted as standards by 
the national medical community for diabetes care. 
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2) Program Objectives 
The objective of this program is to help the Grady North Fulton Health Center or any other 
community healthcare facility implement the evidence-based diabetes guidelines. The ultimate 
goal of implementation is to improve the delivery of effective preventive health care services 
and promote diabetes preventive behaviors in order to prevent diabetes, its complications and 
disabilities, and the burden associated with the disease. 
Diabetes can affect many parts of the body and can lead to serious complications such as 
blindness, kidney damage, and lower-limb amputations. Working together, people with 
diabetes, their support network, and their health care providers can reduce the occurrence of 
these and other diabetes complications. Proven methods for reducing diabetes complications 
include by controlling the levels of blood glucose, blood pressure, and blood lipids, and 
receiving other preventive care practices in a timely manner. 
3) Program Rationale 
A. The Importance of Diabetes 
The World Health Organization (WHO) estimates that there are more than 220 million people 
worldwide living with diabetes. WHO projects diabetes deaths will double between 2005 and 
2030. (WHO, 2011) 
According to the Center for Disease Control and Prevention (CDC), diabetes affects 25.8 million 
people in the U.S. This accounts for 8.3% of the U.S. population. Only 18.8 million affected 
persons have a diabetes diagnosis and the remaining 7 million are undiagnosed. In 2010 there 
were 1.9 million people aged 20 or older newly diagnosed. Among people aged 65 or older 
26.9% had diabetes in 2010. (CDC, 2011) 
Diabetes is the leading cause of kidney failure, non-traumatic lower limb amputations, and new 
cases of blindness among adults in the United States. Diabetes is also a major cause of heart 
disease and stroke, and it is the seventh leading cause of death in the United States, appearing 
in 71,382 death certificates as the underlying cause of death and in 160,022 as contributing 
cause of death in 2007. It is also important note that diabetes is likely to be underreported as a 
cause of death. Overall, the risk for death among people with diabetes is about twice that of 
people of similar age without diabetes. (CDC, 2011) 
Pre-diabetes is a condition in which individuals have blood glucose or glycosylated hemoglobin 
(Hb A1C) levels higher than normal but not high enough to be classified as diabetes. People 
with pre-diabetes have an increased risk of developing type 2 diabetes, heart disease, and 
stroke. Estimates based on fasting glucose or hemoglobin A1C levels yields that 35% of U.S. 
adults aged 20 years or older had pre-diabetes (50% of adults aged 65 years or older) between 
2005 and 2008. (CDC, 2011) 
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The 2007–2009 national survey data for people aged 20 years or older indicate that 7.1% of 
non-Hispanic whites, 8.4% of Asian Americans, 11.8% of Hispanics, and 12.6% of non-Hispanic 
blacks had diagnosed diabetes. Among Hispanics, rates were 7.6% for both Cubans and for 
Central and South Americans, 13.3% for Mexican Americans, and 13.8% for Puerto Ricans. (CDC, 
2011) 
Adults with diabetes have heart disease death rates about 2 to 4 times higher than adults 
without diabetes. The risk for stroke is 2 to 4 times higher among people with diabetes. In 
2005–2008, of adults aged 20 years or older with self-reported diabetes, 67% had blood 
pressure greater than or equal to 140/90 millimeters of mercury (mmHg) or used prescription 
medications for hypertension. In the same frame period, 28.5% people with diabetes aged 40 
years or older had diabetic retinopathy, and of these 4.4% had advanced diabetic retinopathy 
that could lead to severe vision loss. (CDC, 2011) 
Patients with diabetes account for 44% of all new cases of kidney failure in 2008. About 60% to 
70% of people with diabetes have mild to severe forms of nervous system damage. The results 
of such damage include impaired sensation or pain in the feet or hands, slowed digestion of 
food in the stomach, carpal tunnel syndrome, erectile dysfunction, or other nerve problems. 
Severe forms of diabetic nerve disease are a major contributing cause of lower-extremity 
amputations. More than 60% of non-traumatic lower-limb amputations occur in people with 
diabetes, and in 2006, about 65,700 non-traumatic lower-limb amputations were performed in 
people with diabetes. (CDC, 2011) 
The estimated cost (direct and indirect) of diabetes in the U. S. in 2007 was $174 billion. The 
direct medical cost was $116 billion and the indirect cost (disabilities, work loss, premature 
mortality) was $58 billion. The medical expenses for people with diabetes are more than two 
times (2.3) higher than for people without diabetes. (CDC, 2011) In the United Kingdom (UK), 
around 10% of National Health Service spending goes on diabetes and its complications. (The 
Lancet, 2010) 
The goal of medical care for people with diabetes is to optimize glycemic control and minimize 
complications. To achieve optimal glucose control, the person with diabetes should be able to 
access health care providers who have expertise in the field of diabetes. Treatment plans must 
also include self-management training and tools, regular and timely laboratory evaluations, 
medical nutrition therapy, appropriately prescribed medications, and regular self-monitoring of 
blood glucose levels. (ADA, 2010) 
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B. Clinical Practice Guidelines 
Disease-specific standards for directing patient management are becoming increasingly 
important. These standards, however, are often not followed because they are not sufficiently 
integrated into the clinical care setting. Medical organizations have shown a growing interest in 
the establishment and dissemination of clinical policies for different practice areas in order to 
improve quality of care. Government agencies have seen practice guidelines as a potentially 
useful tool in promoting a more cost-effective use of resources in health care, and in reducing 
variations in practice styles. (Nilasena & Lincoln, 1995) 
Clinical Practice Guidelines (CPGs) have been developed as one tool to help reduce unexplained 
variation in clinical practice, control cost, and produce better patient outcomes. CPGs are 
statements developed systematically to assist practitioners and patients in choosing 
appropriate health care for specific clinical circumstances. They incorporate available evidence 
on health outcomes into sets of recommendations concerning appropriate management 
strategies for patient with specific conditions. (Chodoff & Crowley, 1995) 
The purposes of CPGs are limiting variations in practice that may signal problems in the quality 
of service; eliminating or reducing unnecessary costs associated with variations in practice; 
influencing health care practice in a scientific direction by providing concise guides to practice 
based on the consensus of experts; providing up-to-date summaries of evidence-based "best 
practices" accessible to practitioners in a format they find usable; and providing a basis for 
educating the public on the value, risks and benefits of diagnostic and therapeutic procedures. 
(Lewis, 1995) 
As defined by the Institute of Medicine (IOM), CPGs are “systematically developed statements 
to assist practitioner and patient decisions about appropriate health care for specific clinical 
circumstances”. (Field & Lohr, 1990) The primary objective of CPGs is to recommend minimum 
standards of care for a specific patient population based on scientific evidence and expert 
opinion. (Clark et al., 2000) 
CPGs can improve the quality of management of diabetes. The use of structured consultation 
prompts for the recording of clinical information recommended by the guidelines improves 
implementation of the guidelines in practice. (Feder et al., 1995) Diabetes is a common disease 
and its diagnosis is quantitative and relatively unambiguous. Chronic management of diabetes 
requires monitoring of several laboratory parameters and serial physical examinations common 
to all patients. (Lobach & Hammond, 1994) 
An analysis by researchers at the CDC suggested that less than 5% of patients with diabetes 
receive care that follows the American Diabetes Association (ADA) guidelines. (Beckles et al., 
1998) Poor adherence to guidelines may occur because physicians are not aware of or do not 
understand the rationale behind the guideline or because patients refuse to undergo 
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recommended interventions. More commonly, however, lack of adherence stems from 
“system” factors, including physicians not remembering screening guidelines in the midst of a 
busy primary care clinic, lack of time to carry out recommended procedures, lack of 
reimbursement, and lack of resources. (Kirkman et al., 2002) 
One study in 1994 demonstrated that the use of Computer Assisted Management Protocol 
(CAMP) resulted in improvement of compliance with diabetes care standards. This 
demonstrates that CAMP is one effective tool by which practice guidelines can be integrated 
into the clinical setting and it also has a potentially important role in the evaluation of the care 
standards themselves. (Lobach & Hammond, 1994) 
In another study the author found that the computer generated reminder system can improve 
physician compliance with established guidelines for diabetes preventive care. This 
improvement may result from the ability of the system to facilitate physician documentation of 
important care items. (Nilasena & Lincoln, 1995) 
Another study showed that reminders programmed into a computerized medical record system 
improved rates of ophthalmology referral, hemoglobin A1C measurement, and nephropathy 
screening in an academic primary care clinic. (Kirkman et al., 1999) 
Similarly, another study showed striking improvements in physiologic measures such as blood 
pressure, lipids, and hemoglobin A1C, process measures, and satisfaction with care in a 
managed care system through use of a multifaceted intervention that included an enhanced 
data management system, use of non-physician providers to perform some examinations, and 
use of protocols and standing orders. (Clark et al., 2001) 
The American Diabetes Association (ADA) has proposed guidelines for the care of diabetic 
patients. The 2011 recommendations were recently published in their journal Diabetes Care as 
“Standards in Medical Care in Diabetes, 2011”. Adherence to these guidelines could potentially 
reduce the complications of the disease by a significant degree. Thus, the successful 
implementation of these guidelines into medical practice could dramatically decrease the 
burden of suffering and the cost of health care for diabetic complications. 
The ADA guidelines address items that should be included in the initial assessment of a patient 
with diabetes and define specific aspects of the initial medical history, physical examination, 
and laboratory assessment. Health care providers may wish to use items from the guideline in 
the initial assessment of their patients. (Clark et al., 2000) 
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Section II: Program Design 
1) Logic Model 
A logic model is a simplified picture of a program, initiative, or intervention that shows the 
logical relationships among the resources that are invested, the activities that take place and 
the benefits or changes that result. The logic model is the “big picture” of the program that 
allows people to better understand the program activities, processes and desired outcomes. 
Logic models provide in a graphic display of boxes and arrows the relationships and linkages of 
the various components of the program. (McKenzie et. al., 2009) 
Creating a logic model is an important part of the program planning process. It should be 
created in the early stage of planning to increase the effectiveness of the program. It should be 
revised frequently to ensure goals are being achieving. In this project a Logic Model was 
developed to guide in the implementation of the diabetes guidelines. The long term goal is to 
improve the delivery of effective preventive health care services in order to prevent diabetes, 
its complications and disabilities, and the burden associated with the disease. 
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2) Recommendations for the Implementation 
Since medical knowledge and technological development rapidly advance, it is extremely 
important to keep the guidelines updated annually. Keeping the guidelines in accordance with 
ADA publications is essential to preserve the validity of the toolkit. 
There are two main dimensions that need to be considered for successful implementation of 
the guidelines and promoting changes in practices: built local ownership from the staff 
responsible for the implementation of the new guideline and ensure that clinical and 
administrative systems are in place to facilitate staff adherence to the guideline. (Farley et al., 
2005) 
In the Army Medical Department (AMEDD) implementation of the Diabetes Practice Guidelines, 
six critical factors were identified that strongly influence how successful new practices were 
integrated into a clinical and administrative process. (Farley et al., 2005) 
These factors are: 
 Visible and consistent commitment by command leadership 
 Ongoing monitoring of progress in carrying out an implementation plan 
 Provision of implementation guidance and support, including toolkits of support materials 
and ready access to staff support and other resources 
 Identification of a physician who is respected local opinion leader to serve as guideline 
champion and lead the implementation activities 
 Provision of adequate dedicated time and resources support for the guideline champion to 
enable them to perform their task effectively 
 Institutionalization of new practices as part of a clinic’s normal routine procedures within a 
finite period. 
It is important for the successful compliance of the guidelines to establish professional 
partnerships with other providers that will complement the services needed for the diabetic 
patient comprehensive care. Important partners to consider would be a Certified Diabetes 
Educator, a Medical Nutrition Therapist, an Ophthalmologist or Optometrist, and a Podiatry. 
The administrative team must contact them and establish proper channels of communication 
and flow to make the provision of services more suitable for the patient. 
3) Timeline 
In order for the program to be implemented smaller tasks were identified and prioritized, and a 
timeline table was created. Planning timelines can assist in defining the tasks and activities 
needed; the laying out of plans over the life of the project; and the monitoring of progress so 
that midcourse correction can be made if needed. (McKenzie et. al., 2009) The timeline 
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recommendations for program planning, implementation, and evaluation are provided in the 
table below.  
It is important to provide some notice in advance to the staff, stakeholders, and clients about 
the implementation of the program. It is necessary to start with an announcement and the 
appointment of a leadership team who will lead program implementation. After this step it is 
necessary to assign responsibilities and roles that healthcare team members will take. 
Preparation of tools, materials, and data input into the diabetes patient registry can be started 
in the first four months of the planning process. Prior to the program “Kick Off” the staff and 
personnel should be trained on all tools that are available. This is the appropriate time to 
collect baseline data for future program evaluation and comparison. 
Celebrating the “Kick Off” on “World Diabetes Day,” November 14th, will bring awareness to the 
global response to diabetes. Six months is enough time for successful implementation and 
adoption of the guidelines. The first process evaluation can be done at the 6th month of the full 
implementation process. 
Timeline Table 
TASKS 
YEAR 1 
MONTHS 
J J A S O N D J F M A M 
Announce the program and leadership √            
Assign responsibilities √            
Prepare the materials and tools √ √ √ √         
Start the patient registry √ √ √ √ √        
Train staff and personnel     √        
Baseline data collection     √        
Celebration of World Diabetes Day      √       
Program “Kick Off”      √       
Full implementation      √ √ √ √ √ √ √ 
Process evaluation           √ √ 
 
4) Program Evaluation 
Any program regardless of the size, nature, and duration must have an appropriate and 
adequate evaluation. The most critical purposes of the program evaluations are to assess and 
improve quality, and determine effectiveness. During the evaluation process, three different 
types of evaluation take place: process evaluation, impact evaluation, and outcome evaluation. 
(McKenzie et. al., 2009) 
The process evaluation is any combination of measurements obtained during the 
implementation of program activities to control, assure, or improve the quality of the program. 
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Impact evaluation focuses on the immediate observable effects of a program, leading to the 
intended outcome of a program. Outcome evaluation focuses on an ultimate goal or product of 
a program or treatment, generally measured in the health field by mortality or morbidity data 
in a population, vital measures, symptoms, signs, or physiological indicators on individuals; this 
evaluation is long term in nature. (McKenzie et. al., 2009) 
The data will need to be collected in three different time periods in the first year of 
implementation: baseline, mid-term evaluation and final evaluation. Since this is a program that 
will be implemented and ongoing, the evaluation must take place periodically. It is appropriate 
for the mid-term evaluation to take place six months after the program is implemented and for 
the final evaluation to occur twelve months after implementation. Later on the program can be 
evaluated every six or twelve months. The data collection at the baseline, mid-term and final 
evaluation will be used to perform both a process and outcome evaluation. 
The baseline data might already be available through the organization or it may have to be 
collected prior to program implementation. The objective of collecting baseline data is to allow 
comparison to determine changes that have occurred since implementation. 
The mid-term evaluation should be performed six months after the implementation of the 
program. The mid-term evaluation is important to determine what is going well and what is not 
going well during the first six months. Conducting a process evaluation at this point will allow 
the organization to make changes in how the program is being run and to address any concerns 
or issues that have appeared. 
The final evaluation should take place twelve months after implementation to determine the 
effectiveness of the program. An outcome evaluation is data dependent and looks at numbers 
and facts in order to determine results. 
To perform the evaluation of this program chart audits of all encounters with diabetic patients 
have to be done. The measurements will be documented and followed from the electronic 
medical records system used in the health center. Some important indicators and variables that 
need to be monitored to perform the evaluation of the program are listed below: 
 Percentage of diabetic patients with Hb A1C less than 6 months old. 
 Percentage of diabetic patients with lipid profile less than 12 months old. 
 Percentage of diabetic patient with nephropathy tests less than 12 months old. 
 Percentage of diabetic patients with an eye dilated exam less than 12 months old. 
 Percentage of diabetic patients with a comprehensive foot exam less than 12 months old. 
 Percentage of diabetic patients that has received the influenza vaccine in the last 12 
months. 
 Percentage of diabetic patients that has received pneumococcal vaccine. 
 Percentage of the Diabetes Flow Sheets up-to-dated. 
12 
 
 Provider compliance: calculated as the number of required guidelines followed over the 
total number of required guidelines, and expressed as percent compliance. 
 Percentage of diabetic patients with blood pressure controlled. 
 Percentage of diabetic patient with glucose blood level under control. 
  
13 
 
Section III: Program Implementation 
This section includes the most relevant information for preventive diabetes care from the 
American Diabetes Association’s “Standards in Medical Care in Diabetes, 2011” and the tools 
designed for the implementation of the guidelines. This toolkit is focused on preventive 
measures and interventions to encourage and empower the entire health care team and 
promote adherence to the guidelines. All the interventions can be collectively performed by the 
health care team, not only by physicians. However, in order to focus on the therapeutic 
guidelines it is necessary to develop a standardized treatment protocol targeted to physicians. 
1) Educational Information for Diabetes Care by Healthcare Personnel 
Diabetes is a chronic illness that requires continuing medical care and ongoing patient self-
management education and support to prevent acute complications and to reduce the risk of 
long-term complications. Diabetes care is complex and requires that many issues, beyond 
glycemic control, be addressed. A large body of evidence exists that supports a range of 
interventions to improve diabetes outcomes. (ADA, 2011) 
These standards of care are intended to provide clinicians, patients, researchers, payers, and 
other interested individuals with the components of diabetes care, general treatment goals, 
and tools to evaluate the quality of care. While individual preferences, comorbidities, and other 
patient factors may require modification of goals, targets that are desirable for most patients 
with diabetes are provided. These standards are not intended to preclude clinical judgment or 
more extensive evaluation and management of the patient by other specialists as needed. The 
recommendations included are screening, diagnostic, and therapeutic actions that are known 
or believed to favorably affect health outcomes of patients with diabetes. (ADA, 2011) 
A. Classification of Diabetes 
The classification of diabetes includes four clinical classes: 
 Type 1 diabetes (results from β-cell destruction, usually leading to absolute insulin 
deficiency) 
 Type 2 diabetes (results from a progressive insulin secretory defect on the background 
of insulin resistance) 
 Other specific types of diabetes due to other causes, e.g., genetic defects in β-cell 
function, genetic defects in insulin action, diseases of the exocrine pancreas (such as 
cystic fibrosis), and drug or chemical-induced (such as in the treatment of HIV/AIDS or 
after organ transplantation) 
 Gestational diabetes mellitus (GDM) (diabetes diagnosed during pregnancy that is not 
clearly overt diabetes) 
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B. Diagnosis of Diabetes 
For decades, the diagnosis of diabetes was based on plasma glucose criteria, either the fasting 
plasma glucose (FPG) or the 2-h value in the 75-g oral glucose tolerance test (OGTT). In 2009, 
the International Expert Committee that included representatives of the ADA, the International 
Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) 
recommended the use of the hemoglobin A1C test to diagnose diabetes, with a threshold of 
≥6.5%, and ADA adopted this criterion in 2010. The diagnostic test should be performed using a 
method that is certified by the National Glycohemoglobin Standardization Program (NGSP) and 
standardized or traceable to the Diabetes Control and Complications Trial (DCCT) reference 
assay. 
The A1C has several advantages to the FPG and OGTT, including greater convenience, since 
fasting is not required; evidence to suggest greater pre-analytical stability; and less day-to-day 
perturbations during periods of stress and illness. These advantages must be balanced by 
greater cost, the limited availability of A1C testing in certain regions of the developing world, 
and the incomplete correlation between A1C and average glucose in certain individuals. The 
established glucose criteria for the diagnosis of diabetes (FPG and 2-h PG) remain valid as well 
(See Table 1). 
 
Table 1: Criteria for the diagnosis of diabetes 
 
A1C ≥ 6.5%. The test should be performed in a laboratory using a method that is NGSP 
certified and standardized to the DCCT assay.* 
OR 
FPG ≥ 126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for at least 8 h.* 
OR 
2-h plasma glucose ≥ 200 mg/dl (11.1 mmol/l) during an OGTT. The test should be performed 
as described by the World Health Organization, using a glucose load containing the 
equivalent of 75 g anhydrous glucose dissolved in water.* 
OR 
In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random 
plasma glucose ≥ 200 mg/dl (11.1 mmol/l). 
 
*In the absence of unequivocal hyperglycemia, result should be confirmed by repeat testing. 
Source: ADA, 2011. 
 
C. Categories of Increased Risk for Diabetes (Pre-Diabetes) 
In 1997 and 2003, the Expert Committee on Diagnosis and Classification of Diabetes Mellitus 
recognized an intermediate group of individuals whose glucose levels, although not meeting 
criteria for diabetes, are nevertheless too high to be considered normal. These persons were 
defined as having impaired fasting glucose (IFG) (FPG levels 100–125 mg/dl [5.6–6.9 mmol/l]) or 
impaired glucose tolerance (IGT) (2-h PG values in the OGTT of 140 –199 mg/dl [7.8 –11.0 
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mmol/l]). It should be noted that the World Health Organization (WHO) and a number of other 
diabetes organizations define the cutoff for IFG at 110 mg/dl (6.1 mmol/l). In addition, it is it is 
reasonable to consider an A1C range of 5.7–6.4% as identifying individuals with high risk for 
future diabetes. (See Table 2) 
Individuals with IFG and/or IGT have been referred to as having pre-diabetes, indicating the 
relatively high risk for the future development of diabetes. IFG and IGT should not be viewed as 
clinical entities in their own right but rather risk factors for diabetes as well as cardiovascular 
disease (CVD). IFG and IGT are associated with obesity (especially abdominal or visceral 
obesity), dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension. 
 
Table 2: Categories of increased risk for diabetes (pre-diabetes)* 
 
FPG 100–125 mg/dl (5.6–6.9 mmol/l): IFG 
OR 
2-h plasma glucose in the 75-g OGTT 140–199 mg/dl (7.8–11.0 mmol/l): IGT 
OR 
A1C 5.7–6.4% 
 
*For all three tests, risk is continuous, extending below the lower limit of the range 
and becoming disproportionately greater at higher ends of the range. 
Source: ADA, 2011. 
 
D. Testing for Diabetes in Asymptomatic Patients 
Testing for diabetes in asymptomatic patient should be considered in adults of any age with 
body mass index (BMI) ≥25 kg/m2 and one or more of the known risk factors for diabetes. 
Because age is a major risk factor for diabetes, testing of those without other risk factors should 
begin no later than age 45 years. Either Hb A1C, FPG, or the 2-h OGTT is appropriate for testing. 
The 2-h OGTT identifies people with either IFG or IGT and thus more people at increased risk for 
the development of diabetes and CVD. It should be noted that the two tests do not necessarily 
detect the same individuals. If tests are normal, repeat testing carried out at least at 3-year 
intervals is reasonable. The appropriate interval between tests is not known. The rationale for 
the 3-year interval is that false negatives will be repeated before substantial time elapses, and 
there is little likelihood that an individual will develop significant complications of diabetes 
within 3 years of a negative test result. (See Table 3) 
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Table 3: Criteria for testing for diabetes in asymptomatic adult individuals 
 
1. Testing should be considered in all adults who are overweight (BMI ≥ 25 kg/m2*) and have additional risk factors: 
 physical inactivity 
 first-degree relative with diabetes 
 high-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander) 
 women who delivered a baby weighing > 9 lb or were diagnosed with GDM 
 hypertension (≥140/90 mmHg or on therapy for hypertension) 
 HDL cholesterol level <35 mg/dl (0.90 mmol/l) and/or a triglyceride level > 250 mg/dl (2.82 mmol/l) 
 women with polycystic ovarian syndrome (PCOS) 
 A1C ≥ 5.7%, IGT, or IFG on previous testing 
 other clinical conditions associated with insulin resistance (e.g., severe obesity, acanthosis nigricans) 
 history of CVD 
2. In the absence of the above criteria, testing for diabetes should begin at age 45 years. 
3. If results are normal, testing should be repeated at least at 3-year intervals, with consideration of more frequent 
testing depending on initial results and risk status. 
 
*At-risk BMI may be lower in some ethnic groups. 
Source: ADA, 2011. 
 
E. Initial Evaluation 
A complete medical evaluation should be performed to classify the diabetes, detect the 
presence of diabetes complications, review previous treatment and glycemic control in patients 
with established diabetes, assist in formulating a management plan, and provide a basis for 
continuing care. Laboratory tests appropriate to the evaluation of each patient’s medical 
condition should be performed. A focus on the components of comprehensive care will assist 
the health care team to ensure optimal management of the patient with diabetes. (See Table 4) 
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Table 4: Components of the comprehensive diabetes evaluation 
Medical history 
• Age and characteristics of onset of diabetes (e.g., diabetic ketoacidosis [DKA], asymptomatic laboratory 
finding) 
• Eating patterns, physical activity habits, nutritional status, and weight history; growth 
and development in children and adolescents 
• Diabetes education history 
• Review of previous treatment regimens and response to therapy (A1C records) 
• Current treatment of diabetes, including medications, meal plan, physical activity 
patterns, and results of glucose monitoring and patient’s use of data 
• DKA frequency, severity, and cause 
• Hypoglycemic episodes 
• Hypoglycemia awareness 
• Any severe hypoglycemia: frequency and cause 
• History of diabetes-related complications 
• Micro-vascular: retinopathy, nephropathy, neuropathy (sensory, including history of foot 
lesions; autonomic, including sexual dysfunction and gastroparesis) 
• Macro-vascular: coronary heart disease (CHD), cerebrovascular disease, peripheral artery 
disease (PAD) 
• Other: psychosocial problems, dental disease 
Physical examination 
• Height, weight, body mass index (BMI) 
• Blood pressure determination, including orthostatic measurements when indicated 
• Fundoscopic examination 
• Thyroid palpation 
• Skin examination (for acanthosis nigricans and insulin injection sites) 
• Comprehensive foot examination: 
• Inspection 
• Palpation of dorsalis pedis and posterior tibial pulses 
• Presence/absence of patellar and Achilles reflexes 
• Determination of proprioception, vibration, and monofilament sensation 
Laboratory evaluation 
• A1C, if results not available within past 2–3 months 
• If not performed/available within past year: 
• Fasting lipid profile, including total, LDL and HDL cholesterol and triglycerides 
• Liver function tests 
• Test for urine albumin excretion with spot urine albumin-to-creatinine ratio 
• Serum creatinine and calculated glomerular filtration rate (GFR) 
• Thyroid- stimulating hormone in type 1 diabetes, dyslipidemia, or women over age 50 years 
Referrals 
• Annual dilated eye exam 
• Family planning for women of reproductive age 
• Registered dietitian for medical nutrition therapy (MNT) 
• Diabetes self-management education (DSME) 
• Dental examination 
• Mental health professional, if needed 
Source: ADA, 2011. 
 
F. Glycosylated Hemoglobin (A1C) 
Because A1C is thought to reflect average glycemia over several months, and has strong 
predictive value for diabetes complications, A1C testing should be performed routinely in all 
patients with diabetes, at initial assessment and then as part of continuing care. Measurement 
approximately every 3 months determines whether a patient’s glycemic targets have been 
reached and maintained. For any individual patient, the frequency of A1C testing should be 
dependent on the clinical situation, the treatment regimen used, and the judgment of the 
clinician. Some patients with stable glycemia well within target may do well with testing only 
twice per year, while unstable or highly intensively managed patients (e.g., pregnant type 1 
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women) may be tested more frequently than every 3 months. The availability of the A1C result 
at the time that the patient is seen (point-of-care testing) has been reported to result in 
increased intensification of therapy and improvement in glycemic control. (See Table 5) 
 
Table 5: Recommendation for A1C testing 
 Perform the A1C test at least two times a year in patients who are meeting treatment 
goals (and who have stable glycemic control). 
 Perform the A1C test quarterly in patients whose therapy has changed or who are not 
meeting glycemic goals. 
 Use of point-of-care testing for A1C allows for timely decisions on therapy changes, 
when needed. 
 
Source: ADA, 2011. 
 
G. Glycemic Goals in Adults 
Glycemic control is fundamental to the management of diabetes. Lowering A1C to below or 
around 7% has been shown to reduce micro-vascular and neuropathic complications of 
diabetes and, if implemented soon after the diagnosis of diabetes, is associated with long-term 
reduction in macro-vascular disease. Therefore, a reasonable A1C goal for many non-pregnant 
adults is <7%. (See Table 6) 
Because additional analyses from several randomized trials suggest a small but incremental 
benefit in micro-vascular outcomes with A1C values closer to normal, providers might 
reasonably suggest more stringent A1C goals for selected individual patients, if this can be 
achieved without significant hypoglycemia or other adverse effects of treatment. Such patients 
might include those with short duration of diabetes, long life expectancy, and no significant 
cardiovascular disease (CVD). Conversely, less stringent A1C goals may be appropriate for 
patients with a history of severe hypoglycemia, limited life expectancy, advanced micro-
vascular or macro-vascular complications, extensive comorbid conditions, and those with 
longstanding diabetes in whom the general goal is difficult to attain despite diabetes self- 
management education (DSME), appropriate glucose monitoring, and effective doses of 
multiple glucose-lowering agents including insulin. 
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Table 6: Glycemic recommendations for non-pregnant adults with diabetes 
A1C  
Pre-prandial capillary plasma glucose  
Peak post-prandial capillary plasma glucose  
• Goals should be individualized based on: 
• duration of diabetes 
• age/life expectancy 
• comorbid conditions 
• known CVD or advanced micro-vascular 
complications 
• hypoglycemia unawareness 
• individual patient considerations 
• More or less stringent glycemic goals may be 
appropriate for individual patients. 
• Post-prandial glucose may be targeted if A1C 
goals are not met despite reaching pre-prandial 
glucose goals. 
< 7.0% 
70–130 mg/dl (3.9–7.2 
mmol/l) 
< 180 mg/dl* (<10.0 mmol/l) 
*Post-prandial glucose measurements should be made 1–2 h after the beginning of the meal, 
generally peak levels in patients with diabetes. 
Source: ADA, 2011. 
 
H. Hypertension/Blood Pressure Control 
Cardiovascular disease (CVD) is the major cause of morbidity and mortality for individuals with 
diabetes, and the largest contributor to the direct and indirect costs of diabetes. The common 
conditions coexisting with type 2 diabetes (e.g., hypertension and dyslipidemia) are clear risk 
factors for CVD, and diabetes itself confers independent risk. Hypertension is a common 
comorbidity of diabetes, affecting the majority of patients, with prevalence depending on type 
of diabetes, age, obesity, and ethnicity. Hypertension is a major risk factor for both CVD and 
micro-vascular complications. In type 1 diabetes, hypertension is often the result of underlying 
nephropathy, while in type 2 diabetes it usually coexists with other cardio-metabolic risk 
factors. 
The recommendation for screening and diagnosis of hypertension is that blood pressure should 
be measured at every routine diabetes visit. Patients found to have systolic blood pressure 
≥130 mmHg or diastolic blood pressure ≥80 mmHg should have blood pressure confirmed on a 
separate day. Repeat systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg 
confirms a diagnosis of hypertension. 
The recommended goals for a blood pressure control are: a systolic blood pressure <130 mmHg 
is appropriate for most patients with diabetes; based on patient characteristics and response to 
therapy, higher or lower systolic blood pressure targets may be appropriate; patients with 
diabetes should be treated to a diastolic blood pressure <80 mmHg. 
Measurement of blood pressure in the office should be done by a trained individual and should 
follow the guidelines established for non-diabetic individuals: measurement in the seated 
position, with feet on the floor and arm supported at heart level, after 5 min of rest. Cuff size 
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should be appropriate for the upper arm circumference. Elevated values should be confirmed 
on a separate day. Because of the clear synergistic risks of hypertension and diabetes, the 
diagnostic cut-off for a diagnosis of hypertension is lower in people with diabetes (blood 
pressure ≥130/80) than those without diabetes (blood pressure 140/90 mmHg). 
I. Dyslipidemia/Lipid Management 
Patients with type 2 diabetes have an increased prevalence of lipid abnormalities, contributing 
to their high risk of CVD. For the past decade or more, multiple clinical trials demonstrated 
significant effects of pharmacologic (primarily statin) therapy on CVD outcomes in subjects with 
CHD and for primary CVD prevention. Low levels of HDL cholesterol, often associated with 
elevated triglyceride levels, are the most prevalent pattern of dyslipidemia in persons with type 
2 diabetes. 
The recommendations for screening of dyslipidemia in diabetic patients are: in most adult 
patients, measure fasting lipid profile at least annually; in adults with low-risk lipid values (LDL 
cholesterol <100 mg/dl, HDL cholesterol >50 mg/dl, and triglycerides <150 mg/dl), lipid 
assessments may be repeated every 2 years. 
J. Nephropathy Screening 
Diabetic nephropathy occurs in 20–40% of patients with diabetes and is the single leading cause 
of end-stage renal disease (ESRD). Persistent albuminuria in the range of 30–299 mg/24 h 
(micro-albuminuria) has been shown to be the earliest stage of diabetic nephropathy in type 1 
diabetes and a marker for development of nephropathy in type 2 diabetes. Micro-albuminuria 
is also a well-established marker of increased CVD risk. Patients with micro-albuminuria who 
progress to macro-albuminuria (300 mg/24 h) are likely to progress to ESRD. Intensive diabetes 
management with the goal of achieving near-normoglycemia has been shown to delay the 
onset of micro-albuminuria and the progression of micro- to macro-albuminuria in patients 
with type 1 and type 2 diabetes. 
As general recommendations to reduce the risk or slow the progression of nephropathy, 
optimize glucose control and blood pressure control. The recommendation for screening are: 
perform an annual test to assess urine albumin excretion in type 1 diabetic patients with 
diabetes duration of 5 years and in all type 2 diabetic patients starting at diagnosis; and 
measure serum creatinine at least annually in all adults with diabetes regardless of the degree 
of urine albumin excretion. The serum creatinine should be used to estimate glomerular 
filtration rate (GFR) and stage the level of chronic kidney disease (CKD), if present. 
K. Retinopathy Screening 
Diabetic retinopathy is a highly specific vascular complication of both type 1 and type 2 
diabetes, with prevalence strongly related to the duration of diabetes. Diabetic retinopathy is 
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the most frequent cause of new cases of blindness among adults aged 20–74 years. Glaucoma, 
cataracts, and other disorders of the eye occur earlier and more frequently in people with 
diabetes. In addition to duration of diabetes, other factors that increase the risk of, or are 
associated with, retinopathy include chronic hyperglycemia, the presence of nephropathy, and 
hypertension. 
As general recommendations to reduce the risk or slow the progression of retinopathy, 
optimize glycemic control and blood pressure control. 
The recommendation for screening of retinopathy are: adults and children aged 10 years or 
older with type 1 diabetes should have an initial dilated and comprehensive eye examination by 
an ophthalmologist or optometrist within 5 years after the onset of diabetes; patients with type 
2 diabetes should have an initial dilated and comprehensive eye examination by an 
ophthalmologist or optometrist shortly after the diagnosis of diabetes; subsequent 
examinations for type 1 and type 2 diabetic patients should be repeated annually by an 
ophthalmologist or optometrist; less frequent exams (every 2–3 years) may be considered 
following one or more normal eye exams; and examinations will be required more frequently if 
retinopathy is progressing. 
L. Neuropathy Screening 
The diabetic neuropathies are heterogeneous with diverse clinical manifestations. They may be 
focal or diffuse. Most common among the neuropathies are chronic sensor-motor diabetic 
peripheral neuropathy (DPN) and autonomic neuropathy. Although DPN is a diagnosis of 
exclusion, complex investigations to exclude other conditions are rarely needed. 
The early recognition and appropriate management of neuropathy in the patient with diabetes 
is important for a number of reasons: 1) non-diabetic neuropathies may be present in patients 
with diabetes and may be treatable, 2) a number of treatment options exist for symptomatic 
diabetic neuropathy, 3) up to 50% of DPN may be asymptomatic and patients are at risk of 
insensate injury to their feet, and 4) autonomic neuropathy and particularly cardiovascular 
autonomic neuropathy is associated with substantial morbidity and even mortality. 
The recommendations for neuropathy screening are: all patients should be screened for distal 
symmetric polyneuropathy at diagnosis and at least annually thereafter, using simple clinical 
tests; and screening for signs and symptoms of autonomic neuropathy should be instituted at 
diagnosis of type 2 diabetes and 5 years after the diagnosis of type 1 diabetes. 
M. Foot Care 
Amputation and foot ulceration, consequences of diabetic neuropathy and/or peripheral 
arterial disease (PAD), are common and major causes of morbidity and disability in people with 
diabetes. Early recognition and management of risk factors can prevent or delay adverse 
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outcomes. The risk of ulcers or amputations is increased in people who have the following risk 
factors: previous amputation, past foot ulcer history, peripheral neuropathy, foot deformity, 
peripheral vascular disease, visual impairment, diabetic nephropathy (especially patients on 
dialysis), poor glycemic control, and cigarette smoking. 
For all patients with diabetes, perform an annual comprehensive foot examination to identify 
risk factors predictive of ulcers and amputations. The foot examination should include 
inspection, assessment of foot pulses, and testing for loss of protective sensation (10-g 
monofilament plus testing any one of: vibration using 128-Hz tuning fork, pinprick sensation, 
ankle reflexes, or vibration perception threshold). 
Provide general foot self-care education to all patients with diabetes. A multidisciplinary 
approach is recommended for individuals with foot ulcers and high-risk feet, especially those 
with a history of prior ulcer or amputation. Refer patients who smoke, have loss of protective 
sensation and structural abnormalities, or have history of prior lower-extremity complications 
to foot care specialists for ongoing preventive care and life-long surveillance.  
Initial screening for peripheral arterial disease (PAD) should include a history for claudication 
and an assessment of the pedal pulses. Consider obtaining an ankle-brachial index (ABI), as 
many patients with PAD are asymptomatic. Refer patients with significant claudication or a 
positive ABI for further vascular assessment and consider exercise, medications, and surgical 
options. 
N. Immunization 
Influenza and pneumonia are common, preventable infectious diseases associated with high 
mortality and morbidity in the elderly and in people with chronic diseases. People with diabetes 
may be at increased risk of the bacteremic form of pneumococcal infection and have been 
reported to have a high risk of nosocomial bacteremia, which has a mortality rate as high as 
50%. Safe and effective vaccines are available that can greatly reduce the risk of serious 
complications from these diseases. 
The recommendations are annually provide an influenza vaccine to all diabetic patients at least 
6 months of age; and administer pneumococcal polysaccharide vaccine to all diabetic patient ≥2 
years of age. A one-time revaccination is recommended for individuals >64 years of age 
previously immunized when they were <65 years of age if the vaccine was administered >5 
years ago. Other indications for repeat vaccination include nephrotic syndrome, chronic renal 
disease, and other immune-compromised states, such as after transplantation. 
O. Diabetes Self-Management Education 
Diabetes self-management education (DSME) is an essential element of diabetes care, and 
national standards for DSME are based on evidence for its benefits. Education helps people 
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with diabetes initiate effective self-management and cope with diabetes when they are first 
diagnosed. Ongoing DSME and support also help people with diabetes maintain effective self-
management throughout a lifetime of diabetes as they face new challenges and treatment 
advances become available. DSME helps patients optimize metabolic control, prevent and 
manage complications, and maximize quality of life in a cost-effective manner. 
DSME is the ongoing process of facilitating the knowledge, skill, and ability necessary for 
diabetes self-care. This process incorporates the needs, goals, and life experiences of the 
person with diabetes. The overall objectives of DSME are to support informed decision-making, 
self-care behaviors, problem-solving, and active collaboration with the health care team to 
improve clinical outcomes, health status, and quality of life in a cost-effective manner. 
The recommendations are: people with diabetes should receive DSME according to national 
standards when their diabetes is diagnosed and as needed thereafter; effective self-
management and quality of life are the key outcomes of DSME and should be measured and 
monitored as part of care; DSME should address psychosocial issues, since emotional well-being 
is associated with positive diabetes outcomes. 
P. Medical Nutrition Therapy 
Medical nutrition therapy (MNT) is an integral component of diabetes prevention, 
management, and self-management education. In addition to its role in preventing and 
controlling diabetes, ADA recognizes the importance of nutrition as an essential component of 
an overall healthy lifestyle. Achieving nutrition-related goals requires a coordinated team effort 
that includes the active involvement of the person with pre-diabetes or diabetes. Because of 
the complexity of nutrition issues, it is recommended that a registered dietitian who is 
knowledgeable and skilled in implementing nutrition therapy into diabetes management and 
education be the team member who provides MNT. 
As general recommendations individuals who have pre-diabetes or diabetes should receive 
individualized MNT as needed to achieve treatment goals, preferably provided by a registered 
dietitian familiar with the components of diabetes MNT. 
Q. Physical Activity 
Exercise is an important part of the diabetes management plan. Regular exercise has been 
shown to improve blood glucose control, reduce cardiovascular risk factors, contribute to 
weight loss, and improve well-being. Furthermore, regular exercise may prevent type 2 
diabetes in high-risk individuals. 
The recommendations are: people with diabetes should be advised to perform at least 150 
min/week of moderate-intensity aerobic physical activity (50–70% of maximum heart rate); and 
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in the absence of contraindications, people with type 2 diabetes should be encouraged to 
perform resistance training three times per week. 
R. Smoking Cessation 
A large body of evidence from epidemiological, case-control, and cohort studies provides 
convincing documentation of the causal link between cigarette smoking and health risks. Much 
of the work documenting the impact of smoking on health did not separately discuss results on 
subsets of individuals with diabetes, but suggests that the identified risks are at least equivalent 
to those found in the general population. Other studies of individuals with diabetes consistently 
demonstrate that smokers have a heightened risk of CVD, premature death, and increased rate 
of micro-vascular complications of diabetes. Smoking may have a role in the development of 
type 2 diabetes. 
The recommendations are: advise all patients not to smoke; and include smoking cessation 
counseling and other forms of treatment as a routine component of diabetes care. 
S. Antiplatelet Agents 
Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in 
high-risk patients with previous myocardial infarction or stroke (secondary prevention). Its net 
benefit in primary prevention among patients with no previous cardiovascular events is more 
controversial, both for patients with and without a history of diabetes. 
Consider aspirin therapy (75–162 mg/day) as a primary prevention strategy in those with type 1 
or type 2 diabetes at increased cardiovascular risk (10-year risk >10%). This includes most men 
>50 years of age or women >60 years of age who have at least one additional major risk factor 
(family history of CVD, hypertension, smoking, dyslipidemia, or albuminuria). Aspirin should not 
be recommended for CVD prevention for adults with diabetes at low CVD risk (10-year CVD risk 
<5%, such as in men <50 and women <60 years of age with no major additional CVD risk 
factors), since the potential adverse effects from bleeding likely offset the potential benefits. 
For patients with CVD and documented aspirin allergy, clopidogrel (75mg/day) should be used. 
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2) Tools for the Implementation 
A. Diabetes Flow Sheet 
A flow sheet is simply a one page form that gathers all the patient information regarding a 
condition, in this program the condition addressed is diabetes. The flow sheet would be stored 
in the patient chart and serves as a reminder of care and a record of whether goals have been 
met. While flow sheets can be easy and effective tools on paper, they become infinitely more 
valuable when combined with computerized data. Computerized programs offer automatic 
reminders when patients need certain service and provide an easy way to track patient data 
overtime. (White, 2000) 
Diabetes flow sheets can be used to promote better adherence to guidelines when it comes to 
assessing and treating diabetes. In one study in 54 family practice offices in New Jersey and 
Pennsylvania, it was found that diabetes flow sheets were used in 23% of medical records of 
patients with diabetes. The use of flow sheets was associated with better mean guideline 
adherence scores for the assessment and the treatment of diabetes. (Hahn, 2008) 
The Canadian Diabetes Association (CDA) designed a Diabetes Flow Sheet (using the CDA 
clinical practice guidelines) to assist primary care practitioners in treating their patients and to 
provide ongoing feedback. This feedback helps primary care practitioners to attain and 
maintain compliance with their CPGs. Using this tool primary care practitioners have access to 
care guidelines and directed assistance to achieve targets. They have a tool that is practical and 
easy to use. Patients’ treatment plans are continuously audited improving outcome and 
reducing morbidity and mortality. Overall, the participating physicians did improve standards of 
care and guideline compliance in their respective practices as a result of this project. (Patasi & 
Conway, 2008) 
In this toolkit a Diabetes Flow Sheet was developed according to the ADA “Standards in medical 
care in diabetes, 2011” to facilitate the implementation and adherence to the diabetes 
guidelines at Grady North Fulton Health Center. This flow sheet is intended to be part of each 
diabetic patient’s medical chart. It is strongly suggested to design and use the flow sheet in an 
electronic format integrated with the electronic health information system used in the facility. 
(See Appendix C) 
The Diabetes Flow Sheet will hold the patient information and the measures of the standards. 
Every column will represent the date of an assessment and will contain the measures by date. 
Thus, in a single page the physician will have all the information relevant to diabetes care and 
can determine what needs to be done afterwards. If the flow sheet is integrated with the 
electronic medical records it can be filled automatically, if not, anyone from healthcare team 
can do it before or during the patient-physician encounter. 
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B. Patient Registry 
A patient registry is an organized system that collect uniform data (clinical and other) to 
evaluate specified outcomes for a population defined by a particular disease, condition, or 
exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. 
(Gliklich & Dreyer, 2010) 
The World Health Organization (WHO) defined registries in health information systems as “a file 
of documents containing uniform information about individual persons, collected in a 
systematic and comprehensive way, in order to serve a predetermined purpose.” (Brooke, 
1974) 
A disease registry is one type of clinical information system that is effective in supporting new 
models for delivering chronic care. By tracking patient information, a disease registry helps 
physician and other members of the care team to identify and reach out to patients with gaps 
in care. It also prompts them to ensure that appropriate and timely care is provided during 
patient visits. (Metzger, 2004) 
Electronic patient registries can help to reduce barriers to comprehensive care by improving 
record-keeping and targeted care. It has been suggested that diabetes management programs 
are successful in improving diabetes outcomes only when a registry is in place. (Hummel, et al. 
2003) 
Patient registries identify relevant sub-populations of patients for proactive care, which 
includes timely preventive and chronic care reminders and prompts to ensure that patients 
receive care at appropriate intervals. Registries are vital for providing high-quality care. (AAFP, 
2007)  
The patient registry is an important tool that will help to implement the diabetes guidelines and 
keep track of diabetic patients of the clinic. This tool is intended to keep patient’s information 
up-to-date, defining goals and services they need to improve outcomes. Having a registry with 
the list of all diabetic patients and their important clinical measures would help the healthcare 
team to quickly identify which patients needs a reminder phone call, a new test or a referral to 
the specialist. Many of the data management and scheduling task can be performed by a 
clerical person supervised by a nurse or a physician. 
Using a commercially available spreadsheet program, such as Microsoft Excel, a list (or registry) 
of the patients with a given chronic disease can be easily created.  The registry can be used to 
track key measures and remind staff automatically when patients need certain labs and 
preventive services. Such lists can be accessed and managed by anyone on the staff (including 
nurses, medical assistants and administrative staff) with minimal training. The most difficult 
part of creating this spreadsheet is the initial data entry. This can be done over several months 
by assigning the job to a specific staff member or by hiring a part-time data-entry clerk to 
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perform the job. Once the initial worksheet has been created, any staff member can be 
assigned to the maintenance aspects. (Ortiz, 2006) 
In this toolkit a Diabetes Registry spreadsheet was developed according to the ADA “Standards 
in medical care in diabetes, 2011” to facilitate the implementation and adherence to the 
diabetes guidelines at Grady North Fulton Health Center. This registry is intended to be used as 
a complement in the delivery of care of diabetic patients, using information from individual 
medical records and the Diabetes Flow Sheet. The database will need a person to provide 
maintenance and keep all the patient information up-dated. In addition this person will be 
responsible for effective communication with patients when it is needed. In this toolkit a 
Diabetes Reminded Letter is also provided to use it with the registry.  
Ten diabetes target values were selected for monitoring according to the ADA standards: blood 
pressure, hemoglobin A1C, lipids profile (LDL, HDL, and triglycerides), kidney function tests 
(micro-albuminuria and creatinine), eye exam, foot exam, and influenza vaccination. The 
spreadsheet is programmed to change the color of cells to indicate values or services that need 
to be addressed for each patient. Red is present when the services are overdue or when any 
value is out of the standard. Yellow is present one month prior to the service being overdue. In 
the hemoglobin A1C column, yellow means that the patients are in the pre-diabetes range. The 
spreadsheet developed can be found in the appendixes with one example. (See Appendix D & 
E) 
C. Diabetes Reminder Letter 
A Diabetes Reminder Letter can be used as a complement to the Diabetes Registry. When a 
patient is not in compliance with standards, a reminder letter can be sent to let them know 
what needs to be done before the next visit. The letter will basically remind the patient to 
schedule an appointment and to take the tests needed in the lab. A template diabetes reminder 
letter was developed and is included in this toolkit. (See Appendix F) 
The Diabetes Reminder Letter was adapted from the one developed by Family Care Network, 
Copyright © 2000 American Academy of Family Physicians, and can be downloaded at:  
http://www.aafp.org/fpm/20000900/diabetesreminderletter.pdf  
D. Eye Referral Form  
Early detection and treatment of diabetic eye disease can prevent blindness, yet many persons 
with diabetes lack regular eye care. In addition, laser therapy applied to advanced diabetic 
proliferative retinopathy reduces the risk of severe vision loss by 50% or more. However, about 
a third of people with diabetes have never had ophthalmologic examinations and more than 
half of these individuals have eye disease. (Will, 1994) 
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A Retinal Eye Exam Communication Form was designed and it was already in use by Grady 
North Fulton Health Center. The patients take it to their eye doctors to fill it and they bring it 
back to the clinic to be storage in their medical charts. The fulfillment of the form guarantees 
the performance of a dilated eye exam by a specialist and promotes the patient participation 
and responsibility in their own diabetes care. 
This form is included in this toolkit to be part of the implementation of the diabetes guidelines. 
It starts with the patient instruction. It has two sections; the section one is to be filled by the 
patient and the section two is to be filled by the eye care provider. (See Appendix G)  
E. Annual Comprehensive Diabetes Foot Exam Form 
The comprehensive diabetes foot exam is a detailed, annual physical examination of feet, 
combined with an educational and counseling session, performed on people with diabetes. 
Nerve damage, poor circulation and trouble fighting infections, can make foot problems very 
serious for people with diabetes. The goal of the examination is to identify any changes in the 
feet, prevent problems and reduce the risk of amputations. The exam should only take about 
15-20 minutes and will not include the treatment of corns, calluses or nails. 
The Annual Comprehensive Diabetes Foot Exam Form is a tool that documents the inspection of 
the skin, hair, and nails, examination of musculoskeletal structures, pedal pulses, and protective 
sensation, assessment of risk for foot problems, assessment of footwear, and completing a 
management plan. (National Diabetes Education Program, 2000) 
A physician or any other trained health care provider should conduct the foot exam. This form 
is very easy to fill and can be filled by the physician or the nurse. Every diabetic patient must 
have one of this forms in their medical record chart, the exam must be performed annually or 
in every visit if the patient have complication. If any complication is founded the patient must 
has to be referred to a podiatry provider. (See Appendix H) 
 This form is provided by the National Diabetes Education Program and it is available without 
cost to any provider and can be downloaded at:  
http://www.chronicconditions.org/clearinghouse/doc/foot_exam_form.pdf 
F. 10-g Monofilament Test 
The neurological evaluation of the foot is an important part of the comprehensive diabetic foot 
exam. The clinical exam recommended, however, is designed to identify loss of protective 
sensation (LOPS) rather than early neuropathy. The clinical examination to identify LOPS is 
simple and requires no expensive equipment. Five simple clinical tests are considered useful in 
the diagnosis of LOPS in the diabetic foot: the 10-g monofilament, vibration using 128-Hz tuning 
fork, pinprick sensation, ankle reflexes, and vibration perception threshold testing (VPT). Ideally 
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two of these should be regularly performed during the screening exam. Normally the 10-g 
monofilament and one other test are performed. (Boulton, et al. 2008) 
Many prospective studies have confirmed that loss of pressure sensation using the 10-g 
monofilament is highly predictive of subsequent ulceration. Nylon monofilaments are 
constructed to buckle when a 10-g force is applied; loss of the ability to detect this pressure at 
one or more anatomic sites on the plantar surface of the foot has been associated with loss of 
large-fiber nerve function. (Boulton, et al. 2008) 
The nylon monofilament test is a simply performed office test to diagnose patients at risk for 
ulcer formation due to peripheral sensory neuropathy. The test is abnormal if the patient 
cannot sense the touch of the monofilament when it is pressed against the foot with just 
enough pressure to bend the filament.  
The sensory testing device is a 5.07 (10-gram) Semmes-Weinstein nylon monofilament 
mounted on a holder that has been standardized to deliver a 10-gram force when properly 
applied. Research has shown that a person who can feel the 10-gram filament in the selected 
sites is at reduced risk for developing ulcers. Because sensory deficits appear first in the most 
distal portions of the foot and progress proximally in a “stocking” distribution, the toes are the 
first areas to lose protective sensation. (National Diabetes Education Program, 2000) 
The technique for testing pressure perception with the 10-g monofilament is: 
 The sensory exam should be done in a quiet and relaxed setting. 
 The patient must not watch while the examiner applies the filament. 
 Test the monofilament on the patient’s hand so he/she knows what to anticipate. 
 The five sites to be tested are indicated on the examination form. (See Diagram C) 
 Apply the monofilament perpendicular to the skin’s surface. (See Diagram A) 
 Apply sufficient force to cause the filament to bend or buckle, using a smooth, not a jabbing 
motion. (See Diagram B) 
 The total duration of the approach, skin contact, and departure of the filament at each site 
should be approximately 1 to 2 seconds. 
 Apply the filament along the perimeter and NOT on an ulcer site, callus, scar or necrotic 
tissue. 
 Do not allow the filament to slide across the skin or make repetitive contact at the test site. 
 Press the filament to the skin such that it buckles at one of two times as you say “time one” 
or “time two.” Have patients identify at which time they were touched. 
 Randomize the sequence of applying the filament throughout the examination. 
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To document the findings of the 10-gr monofilament test the foot diagram on the Annual 
Comprehensive Diabetes Foot Exam Form should be used. 
G. Group Visits 
Group visits are one way to broaden the doctor-patient relationship and incorporate system 
approaches to education, monitoring, process improvement, behavior modification, and social 
capital. (Gaynor, et. al., 2007) The group visit is a new treatment modality originating in 
managed care for efficient service delivery to patients with chronic health problems. Group 
visits offer promise for delivering care to diabetic patients, as visits are lengthier and can be 
more frequent, more organized, and more educational. Group visits can be a strategy to 
address adherence to guidelines. (Clancy, 2007) 
One of the advantages of group visits is that providers can deliver consistent messages to 
multiple patients simultaneously in group visits, rather than repeating them individually to 
multiple patients. With open general discussions in group visits, patients potentially educate 
each other about referrals and tests experienced; perhaps hearing information from their peers 
resulted in higher acceptance of suggestions from the physicians. Incorporating motivational 
and behavioral strategies emphasizing patients' daily responsibilities and skill building for 
healthy lifestyles compatible with diabetes may affect improvements in clinical outcomes. 
(Clancy, 2007) 
Group visits offer a cost-effective solution. In contrast to the typical 15-minute office visit, a 
two-hour group visit with 20 patients permits ample time for education and discussion. The 
benefits are wide-ranging: reduced health care expenses, improved patient and provider 
satisfaction, higher immunization rates, fewer repeat hospital admissions and fewer visits to 
the emergency department and subspecialists. (Masley, 2000) 
A group visit can be performed following the next suggestions on the three important moments 
of a group visit: before, during, and after. Allow about two hours to plan and two hours to 
conduct a group visit with 20 patients. (Masley, 2000) 
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Before the group visit allow 60 minutes for preparing or obtaining discussion material and/or 
scheduling guest speakers; and 60 minutes for chart review and documentation. 
During the group visit give 30 minutes for collection of subjective and objective data, discussion 
of potential changes in therapy with patients, signing of chart notes and completion of billing 
slips; 15 minutes for group members to introduce themselves and for you to share your agenda 
and time schedule on a flip chart; 45 minutes for didactic information sharing; 15 minutes for 
questions and answers specific to your educational message and to plan the next group visit. 
After the group visit allow 15 minutes for one-on-one meetings with patients to discuss urgent 
or unrelated problems they may bring to your attention during the group session. In our 
experience, one or two patients, at most, have needed attention for minor complaints. 
H. Patient Information Handouts 
Patient information handouts are tools very useful in providing essential information to patient 
that helps them to improve their understanding about the diabetes and engage them in their 
self-care. There is a great amount of websites and organization that provide free or paid 
handouts. In this toolkit it is proposed to use the materials and handouts provided by the 
organization Learning About Diabetes, Inc. This organization is a non-profit, charitable, 
educational corporation dedicated to provide patients, caregivers, and health care 
professionals, easy-to-read highly illustrated, low literacy, and culturally sensitive health care 
information. 
In the Learning About Diabetes website there are multiple types of handouts, booklets, picture 
histories, and comic books. All the information is about diabetes care and it is available for free 
in English and Spanish. In the toolkit we will include the most comprehensive handout to be 
used in the clinic, but at the website there are more available by specific topic. (See Appendix I) 
 The webpage is: http://www.learningaboutdiabetes.org 
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3) Other Resources and Organizations 
American Diabetes Association 
The American Diabetes Association (ADA) is a United States-based association working to fight 
diabetes and to help those affected by diabetes. The association funds research to manage, 
cure and prevent diabetes (including type 1 diabetes, type 2 diabetes, gestational diabetes, and 
pre-diabetes); delivers services to hundreds of communities; provides information for both 
patients and health care professionals; and gives voice to those denied their rights because of 
diabetes. 
The ADA website provides comprehensive information for patients about the disease, care and 
prevention. It has a section for professional providing links to their journals, professional 
education opportunities, and resources. There is also included a series of diabetes animations 
for use in presentations for patients. 
More information can be found at: http://www.diabetes.org 
American Association of Diabetes Educators 
The American Association of Diabetes Educators (AADE) is a multidisciplinary membership 
organization for healthcare professionals who specialize in teaching patients about diabetes 
and how to self-manage the disease. Founded in 1973, AADE works to define the practice of 
diabetes education, increase patients’ access to the services of diabetes educators, and provide 
members with the support and tools to become leaders in the field of diabetes care. On its 
website they provide some resources to patients and physicians. They provide free handouts, 
videos and other resources. 
More information can be found at: http://www.diabeteseducator.org 
National Diabetes Education Program 
The National Diabetes Education Program (NDEP) is a partnership of the National Institutes of 
Health, the Centers for Disease Control and Prevention, and more than 200 public and private 
organizations. The NDEP has developed a huge library of copyright free diabetes education 
materials targeting providers, patients, the media, and ethnic populations. Materials may be 
viewed on the NDEP Web site and many may be downloaded and reproduced. 
More information can be found at: http://www.ndep.nih.gov 
33 
 
MedlinePlus 
MedlinePlus is a website that brings together authoritative information from National Library of 
Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and 
health-related organizations. Pre-formulated MEDLINE searches are included in MedlinePlus 
and give easy access to medical journal articles. MedlinePlus also has extensive information 
about drugs, an illustrated medical encyclopedia, interactive patient tutorials, and latest health 
news. In the diabetes section they have many links with information, pictures, tutorials and 
other resources very useful for patient. 
 More information can be found at: http://www.nlm.nih.gov/medlineplus/diabetes.html 
International Diabetes Federations 
The International Diabetes Federation (IDF) is an umbrella organization of over 200 national 
diabetes associations in over 160 countries. It represents the interests of the growing number 
of people with diabetes and those at risk. IDF’s mission is to promote diabetes care, prevention 
and a cure worldwide. Led by the International Diabetes Federation, the Unite for Diabetes 
campaign secured a United Nations (UN) Resolution on diabetes in December 2006. The 
Resolution encourages UN Member States to develop national policies for the prevention, 
treatment and care of diabetes in line with the sustainable development of their health-care 
systems, taking into account the internationally agreed development goals, including the 
Millennium Development Goals (MDG). The IDF has developed a global guideline for type 2 
diabetes. 
More information can be found at: http://www.idf.org 
World Diabetes Day 
World Diabetes Day is celebrated every year on November the 14th. The World Diabetes Day 
campaign is led by the International Diabetes Federation (IDF) and its member associations. 
Created by the Federation and the World Health Organization in 1991, World Diabetes Day is an 
official United Nation’s World Day. The campaign draws attention to issues of paramount 
importance to the diabetes world and keeps diabetes firmly in the public spotlight. You can 
access to the materials available at their webpage and celebrate the date with your patients. 
More information can be found at: http://www.worlddiabetesday.org 
Diabetes Recognition Program 
In 1997, the National Committee for Quality Assurance (NCQA) and the American Diabetes 
Association (ADA) developed and launched the Diabetes Physician Recognition Program (DPRP) 
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to help identify physicians providing quality diabetes care. Recognition is contingent on a 
physician or medical group demonstrating provision of care consistent with performance 
measures based on practice guidelines for managing diabetes. The DPRP-recognized physicians 
and groups are publicized through health plan provider directories and on the NCQA’s Web site. 
More information can be found at: http://www.ncqa.org/tabid/139/Default.aspx 
Bridges to Excellence Initiative:  Diabetes Care Link 
Bridges to Excellence is a multistate, multiemployer coalition developed by employers, 
physicians, healthcare service researchers, and other industry experts to identify and reward 
quality across the healthcare system. Diabetes and BP control are a significant part of the pay-
for-performance quality measurements, because this effort is built around the NCQA’s 
recognition programs. The specific initiative that is part of the Bridges to Excellence program is 
called Diabetes Care Link. Physicians who demonstrate they are top performers in diabetes care 
can earn up to $80 per year for each person with diabetes covered by a participating employer. 
To participate, physicians must demonstrate that their performance with diabetes management 
is consistent with the standards set by the NCQA/ADA’s DPRP. 
More information can be found at: http://www.bridgestoexcellence.org 
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Appendix A: Logic Model 
The Logic model includes basically three components: inputs (or resources), outputs (or 
activities), and outcomes (or results or effects). The inputs or resources include the human, 
financial, organizational, and community resources a program has available to direct toward 
doing the work. The outputs or the program activities are what the program does with the 
resources. Activities are the processes, tools, events, technology, and actions that are an 
intentional part of the program implementation. These interventions are used to bring about 
the intended program changes or results. The outputs or results are the direct products of 
program activities and may include types, levels and targets of services to be delivered by the 
program. Outcomes are the specific changes in program participants’ behavior, knowledge, 
skills, status and level of functioning. Short-term outcomes should be attainable within 1 to 3 
years, while longer-term outcomes should be achievable within a 4 to 6 year timeframe. 
(Kellogg Foundation, 2004) 
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Appendix B: Summary Table: ADA Standard of Medical Care in Diabetes, 2011 
 
Table 7: Summary of the ADA standard of medical care in diabetes, 2011 
Assessment Frequency of monitoring Goal Comments 
Glycemic control    
Glycosylated 
hemoglobin (A1C) 
2 times a year; quarterly in 
uncontrolled patients 
≤7%  
Pre-prandial capillary 
plasma glucose  
As necessary for glycemic 
control 
70–130 mg/dl (3.9–7.2 mmol/l)  
Peak post-prandial 
capillary plasma glucose 
As necessary for glycemic 
control 
< 180 mg/dl* (<10.0 mmol/l) Post-prandial glucose 
measurements should be 
made 1–2 h after the 
beginning of the meal, 
generally peak levels in 
patients with diabetes. 
Blood pressure Each visit < 130/80 mmHg  
Lipid profile Annually; if low risk values 
every 2 years  
  
LDL cholesterol  <100 mg/dl  
HDL cholesterol  >50 mg/dl  
Triglycerides  <150 mg/dl  
Nephropathy    
Test for micro-
albuminuria 
Annually <30 mg/24 h  
Serum creatinine Annually <1.5 mg/dl Should be used to estimate 
GFR and stage the level of 
chronic kidney disease (CKD), 
if present 
Retinopathy    
Dilated eye examination 
by an ophthalmologist 
or optometrist. 
Annually Normal Refer to ophthalmologist 
Neuropathy    
Foot examination Annually No complication Refer to podiatrist 
Immunizations    
Influenza vaccine Annually N/A Recommended for all patient 
≥6 months old 
Pneumococcal vaccine One-time. Revaccination is 
recommended for individuals 
>64 years of age previously 
immunized when they were 
<65 years of age if the 
vaccine was administered >5 
years ago 
N/A Recommended to all patients 
≥2 years of age 
Diabetes self-management 
education 
At diagnosis and as needed 
thereafter 
Healthy diabetes management 
with metabolic control 
Refer to diabetes educator 
Medical nutrition therapy As needed Healthy eating and weight control Refer to a dietitian familiar 
with the components of 
diabetes MNT 
Physical activity Each visit 150 minutes per week of 
moderate-intensity aerobic 
physical activity and resistance 
training three times per week 
Exercise counseling related to 
type, frequency, 
duration, and intensity 
Smoking cessation Each visit No smoking Refer to smoking cessation 
counseling 
Source: ADA, 2011. 
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Appendix C: Diabetes Flow Sheet 
 
 
DIABETES FLOW SHEET 
Grady North Fulton Health Center, Grady Health System 
  
PATIENT   HEIGHT     
PROVIDER   DATE OF BIRTH     
MR#   DATE OF DX.     
              
STANDARD GOAL FREQUENCY 
DATE DATE DATE DATE 
        
Weight N/A each visit         
BMI <25 each visit         
Blood pressure <130/80mmhg each visit         
Hb A1C ≤ 7% q 4 - 6 month*         
LDL Cholesterol <100mg/dl annually         
HDL Cholesterol >50mg/dl annually         
Triglycerides <150mg/dl annually         
Microalbunimuria <30mg/24 h annually         
Creatinine <1.5mg/dl annually         
Eye examination** Normal annually         
Foot examination Normal annually         
Influenza vaccine Received annually         
Pneumococcal vaccine Received one-time***         
Review dietary pattern Appropriate each visit         
Review physical activity Appropriate each visit         
Review smoking status No smoking each visit         
              
* 2 times a year in controlled patients; quarterly in uncontrolled patients. 
** Dilated eye examination by an ophthalmologist or optometrist. 
*** Revaccination is recommended in >64 years of age previously immunized when they were <65 years  if the vaccine was administered >5 
years ago 
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Appendix D: Diabetes Registry Spreadsheet 
  
N
A
M
E
M
R
#
P
R
O
V
ID
ER
D
A
TE
 L
A
ST
 
V
IS
IT
SY
ST
O
LI
C
 
B
LO
O
D
 
P
R
ES
SU
R
E
D
IA
ST
O
LI
C
 
B
LO
O
D
 
P
R
ES
SU
R
E
A
1
C
 (%
)
D
A
TE
 L
A
ST
 
A
1
C
LD
L 
(M
G
/D
L)
H
D
L 
(M
G
/D
L)
TR
YG
LI
C
ER
I
D
ES
 
(M
G
/D
L)
D
A
TE
 L
A
ST
 
LI
P
ID
 
P
R
O
FI
LE
M
IC
R
O
A
B
U
M
IN
U
R
IA
 
(M
G
/2
4
H
R
)
D
A
TE
 L
A
ST
 
M
IC
R
O
A
LB
U
M
IN
U
R
IA
C
R
EA
TI
N
IN
E 
(M
G
/D
L)
D
A
TE
 L
A
ST
 
C
R
EA
TI
N
IN
E
D
A
TE
 L
A
ST
 
EY
E 
EX
A
M
D
A
TE
 L
A
ST
 
FO
O
T 
EX
A
M
D
A
TE
 L
A
ST
 
FL
U
 
V
A
C
C
IN
A
TI
O
N
D
IA
B
ET
ES
 R
EG
IS
TR
Y
G
ra
d
y 
N
o
rt
h
 F
u
lt
o
n
 H
e
al
th
 C
e
n
te
r,
 G
ra
d
y 
H
e
al
th
 S
ys
te
m
40 
 
Appendix E: Diabetes Registry Spreadsheet Example 
 
  
41 
 
Appendix F: Diabetes Reminder Letter 
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Appendix G: Retinal Eye Exam Communication Form 
 
 Source: Grady North Fulton Health Center 
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Appendix H: Annual Comprehensive Diabetes Foot Exam Form 
 
 Available at: http://www.chronicconditions.org/clearinghouse/doc/foot_exam_form.pdf 
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Appendix I: Patient Information Handouts 
 
 
Available in English and Spanish at: http://www.learningaboutdiabetes.org 
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Available in English and Spanish at: http://www.learningaboutdiabetes.org 
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Available in English and Spanish at: http://www.learningaboutdiabetes.org 
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Available in English and Spanish at: http://www.learningaboutdiabetes.org 
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Appendix J: Sample Posters to Celebrate the World Diabetes Day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Available in English and Spanish at: http://www.worlddiabetesday.org/en/materials/campaign-posters-0 
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Available in English and Spanish at: http://www.worlddiabetesday.org/en/materials/campaign-posters-0 
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Appendix K: Executive Summary: Standards of Medical Care in Diabetes, 2011 
 
Available at: http://care.diabetesjournals.org/content/34/Supplement_1 
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